NZ333500A - Vaccines comprising HIV gp120 envelope polypeptides from vaccinees vaccinated with an earlier HIV gp120 vaccine and subsequently infected with HIV - Google Patents

Vaccines comprising HIV gp120 envelope polypeptides from vaccinees vaccinated with an earlier HIV gp120 vaccine and subsequently infected with HIV

Info

Publication number
NZ333500A
NZ333500A NZ333500A NZ33350097A NZ333500A NZ 333500 A NZ333500 A NZ 333500A NZ 333500 A NZ333500 A NZ 333500A NZ 33350097 A NZ33350097 A NZ 33350097A NZ 333500 A NZ333500 A NZ 333500A
Authority
NZ
New Zealand
Prior art keywords
hiv
vaccinated
vaccine
vaccinees
vaccines
Prior art date
Application number
NZ333500A
Other languages
English (en)
Inventor
Phillip W Berman
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of NZ333500A publication Critical patent/NZ333500A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NZ333500A 1996-07-08 1997-07-03 Vaccines comprising HIV gp120 envelope polypeptides from vaccinees vaccinated with an earlier HIV gp120 vaccine and subsequently infected with HIV NZ333500A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67673796A 1996-07-08 1996-07-08
PCT/US1997/009690 WO1998001564A1 (en) 1996-07-08 1997-07-03 Hiv envelope polypeptides and vaccine

Publications (1)

Publication Number Publication Date
NZ333500A true NZ333500A (en) 2000-09-29

Family

ID=24715764

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ333500A NZ333500A (en) 1996-07-08 1997-07-03 Vaccines comprising HIV gp120 envelope polypeptides from vaccinees vaccinated with an earlier HIV gp120 vaccine and subsequently infected with HIV

Country Status (13)

Country Link
US (1) US6090392A (cg-RX-API-DMAC7.html)
EP (1) EP0942988A1 (cg-RX-API-DMAC7.html)
JP (1) JP2000515368A (cg-RX-API-DMAC7.html)
AP (1) AP1282A (cg-RX-API-DMAC7.html)
AU (1) AU727107B2 (cg-RX-API-DMAC7.html)
CA (1) CA2259965A1 (cg-RX-API-DMAC7.html)
ID (1) ID17767A (cg-RX-API-DMAC7.html)
IL (2) IL127701A0 (cg-RX-API-DMAC7.html)
NZ (1) NZ333500A (cg-RX-API-DMAC7.html)
OA (1) OA10954A (cg-RX-API-DMAC7.html)
TW (1) TWI221846B (cg-RX-API-DMAC7.html)
WO (1) WO1998001564A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA975889B (cg-RX-API-DMAC7.html)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562347B1 (en) 1998-03-12 2003-05-13 The United States Of America As Represented By The Department Of Health And Human Services Chemokine-tumor antigen fusion proteins as cancer vaccines
KR20020075789A (ko) 2000-02-04 2002-10-05 듀크 유니버시티 인체 면역결핍 바이러스 백신
WO2001083535A2 (en) * 2000-05-02 2001-11-08 Simon Fraser University Polypeptides for use as a vaccine and/or treatment for hiv infection
AUPS065002A0 (en) 2002-02-20 2002-03-14 Immunaid Pty Ltd Strategy for retroviral immunotherapy
US20030228320A1 (en) * 2000-08-18 2003-12-11 Ashdown Martin Leonard Retroviral immunotherapy
US7754676B2 (en) 2000-09-15 2010-07-13 The United States Of America As Represented By The Department Of Health And Human Services Defensin-antigen fusion proteins
AU2001291050A1 (en) 2000-09-15 2002-03-26 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Viral chemokine-tumur antigen fusion proteins
EP1361886A2 (en) * 2001-02-15 2003-11-19 The Gov. of USA, as represented by the Secretary, Dept. of Health and Human services, National Institutes of Health Methods and compositions for inhibiting hiv-coreceptor interactions
AUPS054702A0 (en) * 2002-02-14 2002-03-07 Immunaid Pty Ltd Cancer therapy
WO2004050856A2 (en) * 2002-12-03 2004-06-17 University Of Massachusetts Polyvalent, primary hiv-1 glycoprotein dna vaccines and vaccination methods
AU2004247146A1 (en) * 2003-06-12 2004-12-23 Vaxgen, Inc. HIV-1 envelope glycoproteins having unusual disulfide structure
US8076060B2 (en) * 2003-08-04 2011-12-13 Emil William Chynn Vaccination and immunotherapy as new therapeutic modalities in the treatment of glaucoma
DK1692516T3 (da) * 2003-10-24 2011-02-28 Immunaid Pty Ltd Terapifremgangsmåde
DK1805510T3 (da) * 2004-09-08 2012-04-30 Immunaid Pty Ltd Terapeutisk strategi til behandling af autoimmune og degenerative sygdomme
PT1794327T (pt) * 2004-09-14 2017-01-24 Argos Therapeutics Inc Amplificação independente de estirpes de patogénios e vacinas para os mesmos
JP2009509970A (ja) * 2005-09-22 2009-03-12 プロサイ インコーポレイテッド 酵母突然変異体において産生されるグリコシル化ポリペプチドおよびその使用方法
WO2009017743A2 (en) 2007-07-30 2009-02-05 Argos Therapeutics, Inc. Improved primers and probes for the amplification and detection of hiv gag, rev and nef polynucleotides
KR101701198B1 (ko) 2008-06-19 2017-02-01 배리에이션 바이오테크놀로지스 아이엔씨. 인플루엔자를 치료하기 위한 조성물 및 방법
PT2435825E (pt) 2009-05-27 2015-11-02 Biotempus Ltd Métodos para o tratamento de doenças
MX2012000372A (es) 2009-07-06 2012-02-28 Variation Biotechnologies Inc Metodos para preparar vesiculas y formulaciones producidas a partir de las mismas.
US9907746B2 (en) 2009-07-06 2018-03-06 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
CA2793959C (en) 2010-03-25 2019-06-04 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
CA2840079C (en) 2010-07-06 2018-07-03 Variation Biotechnologies Inc. Compositions and methods for treating influenza
US10736844B2 (en) 2011-01-13 2020-08-11 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
SI2691530T1 (en) 2011-06-10 2018-08-31 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
WO2013104995A2 (en) 2012-01-12 2013-07-18 Variation Biotechnologies, Inc. Compositions and methods for treating viral infections
CN104244984B (zh) 2012-01-27 2020-03-31 变异生物技术公司 用于治疗剂的方法和组合物
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
WO2014089152A1 (en) 2012-12-04 2014-06-12 University Of Maryland, Baltimore Hiv-1 env-binding antibodies, fusion proteins, and methods of use
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
EP3069730A3 (en) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU600658B2 (en) * 1984-12-24 1990-08-23 Genentech Inc. Molecularly cloned acquired immunodeficiency syndrome polypeptides and their methods of use
ES2102347T3 (es) * 1987-02-20 1997-08-01 Genentech Inc Metodos y composiciones para la utilizacion de polipeptidos env y anticuerpos anti-env de hiv.
IL89118A0 (en) * 1988-02-03 1989-08-15 Microgenesys Inc Vaccine containing polypeptides derived from the envelope gene of human immunodeficiency virus type 1
EP0339504A3 (en) * 1988-04-26 1990-09-12 The Du Pont Merck Pharmaceutical Company Human immunodeficiency virus (hiv) env-coded peptide capable of eliciting hiv-inhibiting antibodies in mammals
US5116740A (en) * 1988-08-16 1992-05-26 Akzo N.V. Method for producing native hiv gp160
AU6523590A (en) * 1989-09-22 1991-04-18 Idec Pharmaceuticals Corporation Novel peptides associated with the cd4 binding region of gp120 and their methods of use
WO1991015512A2 (en) * 1990-04-03 1991-10-17 Genentech, Inc. Hiv envelope polypeptides
JP3494300B2 (ja) * 1990-04-03 2004-02-09 ジェネンテック・インコーポレーテッド Ｈｉｖに対する予防接種のための方法および組成物
CA2164505A1 (en) * 1993-06-07 1994-12-22 Phillip W. Berman Hiv envelope polypeptides

Also Published As

Publication number Publication date
IL127701A0 (en) 1999-10-28
ZA975889B (en) 1998-02-23
TWI221846B (en) 2004-10-11
CA2259965A1 (en) 1998-01-15
AU3567797A (en) 1998-02-02
AP9901432A0 (en) 1999-03-31
WO1998001564A1 (en) 1998-01-15
OA10954A (en) 2001-10-25
IL127701A (en) 2006-08-01
AU727107B2 (en) 2000-11-30
EP0942988A1 (en) 1999-09-22
AP1282A (en) 2004-06-09
JP2000515368A (ja) 2000-11-21
US6090392A (en) 2000-07-18
ID17767A (id) 1998-01-22

Similar Documents

Publication Publication Date Title
NZ333500A (en) Vaccines comprising HIV gp120 envelope polypeptides from vaccinees vaccinated with an earlier HIV gp120 vaccine and subsequently infected with HIV
AU2774389A (en) Recombinant vaccinia virus mva
IL140217A0 (en) Particles of hcv envelope proteins: use for vaccination
WO1998037095A3 (en) Recombinant pox virus for immunization against muc1 tumor-associated antigen
MY136081A (en) Modified hiv - 1gag p17 peptide and immunogenic composition
AU2497292A (en) Flavivirus envelope proteins with increased immunogenicity for use in immunization against virus infection
WO1993000365A3 (en) Hepatitis c virus (hcv) polypeptides
AU3762889A (en) Hiv-3 retrovirus and its use
CA2660355A1 (en) Polynucleotide vaccine formulation against pathologies of the horse
NO863803L (no) Vaksiner og immunoanalyser for ervervet immunsviktsyndrom (aids).
ATE395932T1 (de) Rekombinanter immunschwächepoxvirus
HUP9900389A3 (en) Mixture of recombinant viruses as polyenv vaccines for hiv, preparation and use thereof
CA2082948A1 (en) Immunogenic peptides, antibodies and uses thereof relating to cd4 receptor binding
AU1353295A (en) Peptides derived from a retrovirus of the HIV group, and their use
GB2331523B (en) Vaccine production of the bacillus anthracis protective antigen
NO912825D0 (no) Fremgangsmaate for fremstilling av cokonjugate vaksiner omfattende immunogenisk protein, hiv-beslektede peptider og anioniske grupper.
AU4826493A (en) Anti-feline immunodeficiency virus (fiv) vaccines
AU630861B2 (en) Recombinant hiv-2 polypeptides
NZ221227A (en) Hiv envelope proteins, antigenic fragments vaccines; and diagnostic methods
IE870507L (en) Bovine virus diarrhea and hog cholera vaccines
DK0762895T3 (da) Syntetisk vaccine til beskyttelse mod infektion med human immundefektvirus
HK126095A (en) Hepatitis a virus vaccines
GB9818133D0 (en) Vaccine
WO1993014206A3 (en) Synthetic peptides for a rubella vaccine
CA2431881A1 (en) Polypeptide inducing hiv-neutralising antibodies

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
EXPY Patent expired